Article Per Year (5 Year)
p-Index From 2021 - 2026
1.554
P-Index
This Author published in this journals
All Journal Indonesia Natural Research Pharmaceutical Journal (INRPJ) SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Berdikari : Jurnal Pengabdian kepada Masyarakat Pharmacy Action Journal
Astiani, Rangki
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemistry Civil Engineering, Building, Construction & Architecture Economics, Econometrics & Finance Health Professions Immunology & microbiology Law, Crime, Criminology & Criminal Justice Medicine & Pharmacology Public Health Social Sciences Other

Published : 11 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 11 Documents
Search

 1   2 
DRUG THERAPY IN PATIENTS WITH GRADE 4 DEXTRA HIP OSTEOARTHRITIS WITH COMORBID HYPERTENSION AND TYPE 2 DIABETES MELLITUS Astiani, Rangki; Piter, Piter; Anggraeni, Ria; Luthfiana, Farisa; Sari, Dini Permata; Ramatillah, Diana Laila; Khan, Khasif
SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Vol 10, No 2 (2025)
Publisher : Universitas 17 Agustus 1945 Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52447/scpij.v10i2.8977

Abstract

Osteoarthritis (OA) is a chronic degenerative disease that affects the joints, especially heavy joints such as the knees and hips. OA often causes chronic pain and limited mobility, which is even more complex when accompanied by comorbid hypertension and type 2 diabetes mellitus. These comorbidities increase the risk of pharmacotherapy side effects and drug interactions, requiring a multidisciplinary approach and careful clinical pharmacy monitoring. The purpose of this report is to review the pharmacotherapy management of grade 4 OA Hip Dextra with comorbid HT and DMT2, assessing the safety, effectiveness, and role of clinical pharmacists in therapy optimization. A retrospective case study was conducted by analyzing the patient's medical records, including anamnesis, physical examination, laboratory, pharmacological therapy, and clinical response. The analysis was conducted based on the national guidelines of the Indonesian Ministry of Health, the 2021 National Formulary, PERKENI 2023, and PAPDI 2021. The patient was given combination therapy of NSAIDs, analgesics, prophylactic antibiotics, muscle relaxants, gastric protection, and supplementation for anemia. Therapeutic adjustments were made according to the patient's response and laboratory parameters. Clinical pharmacy monitoring ensures pain control, mobility, hemoglobin, and blood sugar. A multidisciplinary approach based on national guidelines has been shown to improve the safety and effectiveness of OA therapy with multiple comorbidities.
Co-Authors Didit Sumardiyanto Farisa Luthfiana Firman Firman Halim, Guntoro Khan, Khasif Kristina, Eka Latief, Fahamsyah Hamdan Liandhajani, Liandhajani Muhammad Lukman Hakim, Muhammad Lukman piter, piter Ramatillah, Diana Laila Ria Anggraeni Rizky, Permana Saidah, Andi Sari, Dini Permata Seno, Kukuh Setiadi, Novan Sri Endah Susilowati Sukartiningsih, Yulita Vivian, Maria